Related to ABL Awarded up to $102M in NIH Contract

• Researchers Develop Approach in Mice to Treat Tularemia
  
• Tetraphase Pockets $45M to Progress Next-Generation Tetracyclines
  
• AFFiRiS to Use ProBioGen’s Human Artificial Lymph Node System for Peptide Vaccine Testing
  
• NCI to Conduct Phase I Study with Immatics' Glioblastoma Vaccine
  
• Scancell and ImmuneRegen to Evaluate Combination of Their Vaccine Technologies
  
• Cytheris Scores €12M Financing to Progress IL-7 Pipeline
  
• Sanofi Pasteur Pays Vivalis €3M for Access to Human mAb Platform for Infectious Diseases
  
• The Status of U.S. and European Government Funding for Synthetic Biology
  
• IncellDx to Start U.S. Clinical Trials of HPV Test with $3M Financing
  
• Cellectis to Apply Its Meganuclease Technology to Engineer Lonza Cell Line
  
• Investigators Describe How Bacteria Form Syringe-Like Structure that Helps Infection
  
• FDA Partially Lifts Clinical Hold on Merck Serono’s Anticancer Vaccine
  
• BD Applies Exiqon Technology to Infectious Disease Diagnostics
  
• NIH and Wellcome Trust Pledge $38M for Population-Based Genetic Studies in Africa
  
• Esperion Taps TransGenRx for Protein Production to Support HDL-Related Research
  
• Nonprofit Organizations Join Forces to Evaluate Adjuvants for Pandemic Flu Vaccines
  
• Scancell and Immatics to Explore Combination of Vaccine Technologies for Colorectal Cancer
  
• GSK and EDB Pledge $35M to Augment Green Manufacturing in Singapore
  
• Diabetes Therapy Company Poxel Raises $21M in Series A Financing
  
• NIH to Fund 10 Malaria Research Centers with $14M in the First Year